These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 9704873

  • 1. Dimensional assessment of onset of action of antidepressants: a comparative study of moclobemide vs. clomipramine in depressed patients with blunted affect and psychomotor retardation.
    Jouvent R, Le Houezec J, Payan C, Mikkelsen H, Fermanian J, Millet V, Dufour H.
    Psychiatry Res; 1998 Jul 13; 79(3):267-75. PubMed ID: 9704873
    [Abstract] [Full Text] [Related]

  • 2. The efficacy of reversible monoamine oxidase inhibitors in depressive illness.
    Roth M, Guelfi JD.
    Can J Psychiatry; 1992 Sep 13; 37 Suppl 1():18-24. PubMed ID: 1394027
    [Abstract] [Full Text] [Related]

  • 3. Moclobemide versus clomipramine in the treatment of depression: a multicentre trial in Spain.
    Civeira J, Cervera S, Giner J, Allen SR, Hellstern K, Malanowski H, Wirz R, Klar K.
    Acta Psychiatr Scand Suppl; 1990 Sep 13; 360():48-9. PubMed ID: 2248070
    [Abstract] [Full Text] [Related]

  • 4. Moclobemide versus clomipramine in nonmelancholic, nonpsychotic major depression. A Study group.
    Lecrubier Y, Pedarriosse AM, Payan C, Schmid-Burgk W, Stabl M.
    Acta Psychiatr Scand; 1995 Oct 13; 92(4):260-5. PubMed ID: 8848950
    [Abstract] [Full Text] [Related]

  • 5. Moclobemide versus clomipramine in endogenous depression. A double-blind randomised clinical trial.
    Guelfi JD, Payan C, Fermanian J, Pedarriosse AM, Manfredi R.
    Br J Psychiatry; 1992 Apr 13; 160():519-24. PubMed ID: 1571752
    [Abstract] [Full Text] [Related]

  • 6. Moclobemide versus clomipramine in the treatment of depression: a double-blind multicentre study in Belgium.
    Dierick M, Cattiez P, Franck G, Burton P, Defleur J, Hermans W, Roelandts A, Wolfrum C, Berger M, Hellstern K.
    Acta Psychiatr Scand Suppl; 1990 Apr 13; 360():50-1. PubMed ID: 2248071
    [Abstract] [Full Text] [Related]

  • 7. Moclobemide versus clomipramine in the treatment of depression: a single-centre study, Federal Republic of Germany.
    Funke HJ, Moritz E, Hellstern K, Malanowski H.
    Acta Psychiatr Scand Suppl; 1990 Apr 13; 360():46-7. PubMed ID: 2248069
    [Abstract] [Full Text] [Related]

  • 8. Switch in treatment from tricyclic antidepressants to moclobemide: a new generation monoamine oxidase inhibitor.
    Dingemanse J, Kneer J, Fotteler B, Groen H, Peeters PA, Jonkman JH.
    J Clin Psychopharmacol; 1995 Feb 13; 15(1):41-8. PubMed ID: 7714227
    [Abstract] [Full Text] [Related]

  • 9. Review of comparative clinical trials. Moclobemide vs tricyclic antidepressants and vs placebo in depressive states.
    Stabl M, Biziére K, Schmid-Burgk W, Amrein R.
    J Neural Transm Suppl; 1989 Feb 13; 28():77-89. PubMed ID: 2677244
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of reversible inhibitors of monoamine oxidase-A in various forms of depression.
    Lecrubier Y, Guelfi JD.
    Acta Psychiatr Scand Suppl; 1990 Feb 13; 360():18-23. PubMed ID: 2248063
    [Abstract] [Full Text] [Related]

  • 11. Moclobemide. An update of its pharmacological properties and therapeutic use.
    Fulton B, Benfield P.
    Drugs; 1996 Sep 13; 52(3):450-74. PubMed ID: 8875133
    [Abstract] [Full Text] [Related]

  • 12. Moclobemide versus clomipramine in depressed patients in general practice. A randomized, double-blind, parallel, multicenter study.
    Kragh-Sørensen P, Müller B, Andersen JV, Buch D, Stage KB.
    J Clin Psychopharmacol; 1995 Aug 13; 15(4 Suppl 2):24S-30S. PubMed ID: 7593726
    [Abstract] [Full Text] [Related]

  • 13. Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group.
    J Affect Disord; 1993 Jun 13; 28(2):105-16. PubMed ID: 8354766
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A risk-benefit assessment of moclobemide in the treatment of depressive disorders.
    Norman TR, Burrows GD.
    Drug Saf; 1995 Jan 13; 12(1):46-54. PubMed ID: 7741983
    [Abstract] [Full Text] [Related]

  • 17. Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness.
    Fitton A, Faulds D, Goa KL.
    Drugs; 1992 Apr 13; 43(4):561-96. PubMed ID: 1377119
    [Abstract] [Full Text] [Related]

  • 18. The predictive validity of atypical neurovegetative depressive symptoms identified by the first principal component in the DUAG trial of moclobemide versus clomipramine.
    Bech P, Stage KB, Larsen JK, Vestergaard P, Gram LF, DUAG.
    J Affect Disord; 2012 Nov 13; 140(3):253-9. PubMed ID: 22381949
    [Abstract] [Full Text] [Related]

  • 19. Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo.
    Versiani M, Nardi AE, Figueira IL, Stabl M.
    Acta Psychiatr Scand Suppl; 1990 Nov 13; 360():24-8. PubMed ID: 2123366
    [Abstract] [Full Text] [Related]

  • 20. Moclobemide: therapeutic use and clinical studies.
    Bonnet U.
    CNS Drug Rev; 2003 Nov 13; 9(1):97-140. PubMed ID: 12595913
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.